Efficacy of Etelcalcetide vs Cinacalcet in Hemodialyzed Patients with Secondary Hyperparathyroidism

Efficacy of Etelcalcetide vs Cinacalcet in Hemodialyzed Patients with Secondary Hyperparathyroidism - Efficacy of Etelcalcetide vs Cinacalcet in Hemodialyzed Patients with Secondary Hyperparathyroidism

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000034155

Enrollment

Registered

2018-09-15

Start date

2017-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary Hyperparathyroidism

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The subjects were hemodialysis outpatients at our hospital with high PTH levels and high or normal serum phosphorus or calcium levels. Therefore, according to the 9-section chart for maintaining optimal levels of serum phosphorus and calcium of the Clinical Practice Guideline for the Management of Chronic Kidney Disease-Mineral and Bone Disorder.

Exclusion criteria

Exclusion criteria: Ineligible for the study as judged by the investigator

Design outcomes

Primary

Measure	Time frame
The endpoints were the levels of corrected serum calcium, serum phosphorus, intact PTH, tartrate-resistant acid phosphatase (TRACP)-5b, and bone-type alkaline phosphatase (BAP). The mean corrected serum calcium, serum phosphorus, and intact PTH levels for 24 weeks before the start of treatment with etelcalcetide (pre-treatment values) were compared with those for 24 weeks after the start of treatment (post-treatment values). The mean TRACP-5b and BAP levels at the start of treatment (pre-treatment values) with etelcalcetide were also compared with those for 24 weeks after the start of treatment (post-treatment values). In addition, the endpoints were compared among treatment groups: cinacalcet hydrochloride-free group (n=8), low-dose cinacalcet hydrochloride/etelcalcetide group (switched from cinacalcet hydrochloride <26 mg/day to etelcalcetide; n=29), and high-dose cinacalcet hydrochloride/etelcalcetide group (switched from cinacalcet hydrochloride > 26 mg/day to etelcalcetide; n=13).	—

Measure

Time frame

The endpoints were the levels of corrected serum calcium, serum phosphorus, intact PTH, tartrate-resistant acid phosphatase (TRACP)-5b, and bone-type alkaline phosphatase (BAP). The mean corrected serum calcium, serum phosphorus, and intact PTH levels for 24 weeks before the start of treatment with etelcalcetide (pre-treatment values) were compared with those for 24 weeks after the start of treatment (post-treatment values). The mean TRACP-5b and BAP levels at the start of treatment (pre-treatment values) with etelcalcetide were also compared with those for 24 weeks after the start of treatment (post-treatment values). In addition, the endpoints were compared among treatment groups: cinacalcet hydrochloride-free group (n=8), low-dose cinacalcet hydrochloride/etelcalcetide group (switched from cinacalcet hydrochloride <26 mg/day to etelcalcetide; n=29), and high-dose cinacalcet hydrochloride/etelcalcetide group (switched from cinacalcet hydrochloride > 26 mg/day to etelcalcetide; n=13).

—

Secondary

Measure	Time frame
Whether or not the mean corrected serum calcium level significantly differed between the 19 subjects who underwent a washout period and the 23 subjects who did not, after the start of treatment with etelcalcetide.	—

Countries

Japan

Contacts

Public ContactNaofumi Ikeda

Saitama Sekishinkai Hospital Department of Nephrology

naofumi-ikeda@saitama-sekishinkai.org04-2953-6611

Outcome results